Literature DB >> 29246819

Discordance between self-reported contraceptive use and detection of exogenous hormones among Malawian women enrolling in a randomized clinical trial.

Anuli N Nwaohiri1, Jennifer H Tang2, Frank Stanczyk3, Lameck Chinula2, Stacey Hurst1, Nicole L Davis1, Gerald Tegha2, Lisa Haddad4, Athena P Kourtis5.   

Abstract

OBJECTIVE: The objective was to assess the extent of concordance between self-reported contraceptive use and the presence of contraceptive progestins in serum. STUDY
DESIGN: We evaluated self-reported contraceptive use by using radioimmunoassay to examine baseline serum levels of medroxyprogesterone acetate (MPA) and levonorgestrel (LNG) among 97 Malawian women enrolling in a contraceptive trial.
RESULTS: Twelve percent (12/97) of study participants who reported no hormonal contraceptive use in the previous 6months had either MPA or LNG detected in their serum.
CONCLUSIONS: The observed discordance between self-report and detection of exogenous hormones in serum indicates that caution is warranted when drawing conclusions based on self-reported contraceptive use. Published by Elsevier Inc.

Entities:  

Keywords:  Contraceptive use; Discordance; Levonorgestrel (LNG); Medroxyprogesterone acetate (MPA); Misreporting

Mesh:

Substances:

Year:  2017        PMID: 29246819      PMCID: PMC5840008          DOI: 10.1016/j.contraception.2017.12.007

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  10 in total

1.  Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration.

Authors:  F Z Stanczyk; M Hiroi; U Goebelsmann; P F Brenner; M E Lumkin; D R Mishell
Journal:  Contraception       Date:  1975-09       Impact factor: 3.375

2.  Predictors of noncompliance in an oral contraceptive clinical trial.

Authors:  Carolyn L Westhoff; Anupama T Torgal; Elizabeth R Mayeda; Noa'a Shimoni; Frank Z Stanczyk; Malcolm C Pike
Journal:  Contraception       Date:  2011-11-12       Impact factor: 3.375

Review 3.  Pharmacokinetics of depot medroxyprogesterone acetate contraception.

Authors:  D R Mishell
Journal:  J Reprod Med       Date:  1996-05       Impact factor: 0.142

4.  Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial.

Authors:  Jennifer E Balkus; Elizabeth R Brown; Sharon L Hillier; Anne Coletti; Gita Ramjee; Nyaradzo Mgodi; Bonus Makanani; Cheri Reid; Francis Martinson; Lydia Soto-Torres; Salim S Abdool Karim; Zvavahera M Chirenje
Journal:  Contraception       Date:  2015-10-28       Impact factor: 3.375

5.  Clearance of levonorgestrel from the circulation following removal of NORPLANT subdermal implants.

Authors:  H B Croxatto; S Díaz; M Pavez; H Cárdenas; M Larsson; E D Johansson
Journal:  Contraception       Date:  1988-11       Impact factor: 3.375

6.  A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.

Authors:  Athena P Kourtis; Lisa Haddad; Jennifer Tang; Lameck Chinula; Stacey Hurst; Jeffrey Wiener; Sascha Ellington; Julie A E Nelson; Amanda Corbett; Kristina De Paris; Caroline C King; Mina Hosseinipour; Irving F Hoffman; Denise J Jamieson
Journal:  Contemp Clin Trials       Date:  2016-11-09       Impact factor: 2.226

7.  Pharmacokinetics of levonorgestrel 0.75 mg tablets.

Authors:  Karin Kook; Henry Gabelnick; Gordon Duncan
Journal:  Contraception       Date:  2002-07       Impact factor: 3.375

8.  Social desirability bias in family planning studies: a neglected problem.

Authors:  Gretchen S Stuart; David A Grimes
Journal:  Contraception       Date:  2009-04-22       Impact factor: 3.375

9.  Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.

Authors:  Kimberly K Scarsi; Kristin M Darin; Shadia Nakalema; David J Back; Pauline Byakika-Kibwika; Laura J Else; Sujan Dilly Penchala; Allan Buzibye; Susan E Cohn; Concepta Merry; Mohammed Lamorde
Journal:  Clin Infect Dis       Date:  2015-12-08       Impact factor: 9.079

10.  Misreporting of contraceptive hormone use in clinical research participants.

Authors:  Sharon L Achilles; Felix G Mhlanga; Petina Musara; Samuel M Poloyac; Zvavahera M Chirenje; Sharon L Hillier
Journal:  Contraception       Date:  2017-09-28       Impact factor: 3.375

  10 in total
  3 in total

1.  HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.

Authors:  Renee Heffron; Randy Stalter; Maria Pyra; Kavita Nanda; David W Erikson; Florian Hladik; Steven W Blue; Nicole L Davis; Nelly Mugo; Athena P Kourtis; Jairam R Lingappa; Jared M Baeten
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

2.  Use of traditional and modern contraceptives among childbearing women: findings from a mixed methods study in two southwestern Nigerian states.

Authors:  Anthony Idowu Ajayi; Oladele Vincent Adeniyi; Wilson Akpan
Journal:  BMC Public Health       Date:  2018-05-09       Impact factor: 3.295

3.  Interviewer effects on abortion reporting: a multilevel analysis of household survey responses in Côte d'Ivoire, Nigeria and Rajasthan, India.

Authors:  Katy Footman
Journal:  BMJ Open       Date:  2021-11-19       Impact factor: 3.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.